Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
Hangzhou, CN
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.19% | -4.21% | -12.64% | -8.07% | -20.10% | -13.25% | +5.25% | +69.26% | -66.60% | -66.60% | -66.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+35.2% ★ Q4'25: +93.4% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+145.2% ★ Q4'25: +392.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+25.6% ★ Q4'25: +29.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+18.8% ★ Q4'25: +20.7% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+12.7% ★ Q4'25: +30.5% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-1.3% ★ Q4'25: -1.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.27× ★ Q4'25: 0.12× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
177.91M
est: 202.51M (-12.1%)
|
334.09M
est: 372.43M (-10.3%)
|
527.75M
est: 617.29M (-14.5%)
|
782.48M
est: 792.60M (-1.3%)
|
1.06B
est: 1.06B (+0.0%)
|
1.55B
1.47B – 1.60B
+46.6% YoY
|
2.01B
1.91B – 2.14B
+29.4% YoY
|
2.47B
2.35B – 2.60B
+23.4% YoY
|
| EBITDA |
-208.49M
est: -91.31M (-128.3%)
|
-86.57M
est: -167.93M (+48.5%)
|
-41.60M
est: -127.80M (+67.4%)
|
65.30M
est: -164.10M (+139.8%)
|
231.92M
est: -218.89M (+205.9%)
|
-320.95M
-332.16M – -303.59M
-46.6% YoY
|
-415.16M
-443.07M – -396.05M
-29.4% YoY
|
-512.11M
-539.28M – -486.72M
-23.4% YoY
|
| EBIT |
-218.17M
est: -98.76M (-120.9%)
|
-112.83M
est: -181.62M (+37.9%)
|
-77.48M
est: -154.36M (+49.8%)
|
36.18M
est: -198.20M (+118.3%)
|
198.82M
est: -264.38M (+175.2%)
|
-387.65M
-401.18M – -366.68M
-46.6% YoY
|
-501.44M
-535.14M – -478.35M
-29.4% YoY
|
-618.53M
-651.34M – -587.87M
-23.4% YoY
|
| Net Income |
-199.69M
est: -177.38M (-12.6%)
|
-113.56M
est: -114.08M (+0.5%)
|
-78.73M
est: 23.85M (-430.1%)
|
100.26M
est: 100.51M (-0.3%)
|
244.37M
est: 219.49M (+11.3%)
|
329.67M
315.33M – 344.00M
+50.2% YoY
|
447.45M
429.28M – 465.61M
+35.7% YoY
|
572.52M
534.41M – 610.62M
+28.0% YoY
|
| SGA |
195.87M
est: 185.33M (+5.7%)
|
249.47M
est: 340.83M (-26.8%)
|
277.92M
est: 371.93M (-25.3%)
|
265.76M
est: 477.55M (-44.4%)
|
315.87M
est: 637.02M (-50.4%)
|
934.04M
883.50M – 966.65M
+46.6% YoY
|
1.21B
1.15B – 1.29B
+29.4% YoY
|
1.49B
1.42B – 1.57B
+23.4% YoY
|
| EPS |
-0.68
est: -0.54 (-25.7%)
|
-0.34
est: -0.35 (+2.3%)
|
-0.24
est: 0.07 (-427.9%)
|
0.31
est: 0.31 (+0.0%)
|
0.76
est: 0.71 (+7.5%)
|
1.03
0.97 – 1.06
+45.7% YoY
|
1.37
1.33 – 1.44
+33.4% YoY
|
1.77
1.65 – 1.89
+28.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.26% | 166.5K | 0.59% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 292.6K | 0.65% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 40.6K | 0.42% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 111.5K | 0.72% |
| 5 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 20.9K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 172.0K | 0.55% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 82.3K | 0.74% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 25.2K | 0.35% |
| 9 | iShares MSCI EM IMI Screened UCITS ETF SEDM.L | 0.00% | 30.2K | 0.18% |
| 10 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 58.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhong Zhao | Founder, Chairman & Chief Executive Officer | 9M | — |
| Zheng Li | Senior Vice President, GM of Neurovascular Business & Executive Director | 7M | — |
| Yang Xie | Senior Vice President of Sales & Marketing and Executive Director | 5M | male |
| Quanwei Yuan | Chief Financial Officer & Joint Company Secretary | — | male |
| Sau In Kwan | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2190.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
